Immunic, Inc. is a biotechnology company. Co. is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Co.'s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. We show 28 historical shares outstanding datapoints in our coverage of IMUX's shares outstanding history.
Understanding the changing numbers of IMUX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IMUX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IMUX by allowing them to research IMUX shares outstanding history
as well as any other stock in our coverage universe. |
Free IMUX Email Alerts:
Video: Shares Outstanding Importance
